Topical macrolide immunomodulators: A role in the treatment of vitiligo?

American Journal of Clinical Dermatology

Volumn 7, Issue 1, 2006, Pages 7-12

  Tjioe, Milan ^a   Vissers, Wynand H P M ^a   Gerritsen, Marie Jeanne P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CALCINEURIN INHIBITOR; CLOBETASOL PROPIONATE; CORTICOSTEROID; IMMUNOMODULATING AGENT; MACROLIDE; PIMECROLIMUS; PSORALEN; TSUKUBAENOLIDE;

ACNE; ADRENERGIC ACTIVITY; AUTOIMMUNITY; BURN; BURNING SENSATION; CELL DESTRUCTION; CLINICAL TRIAL; DRUG MECHANISM; DRUG USE; EXCIMER LASER; GENETICS; HUMAN; MELANOCYTE; MOON FACE; PATHOPHYSIOLOGY; PHOTOTHERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; PUVA; REVIEW; SIDE EFFECT; SKIN ATROPHY; SKIN PIGMENTATION; STINGING SENSATION; SURGICAL TECHNIQUE; THEORETICAL STUDY; VITILIGO; WEIGHT GAIN;

ADMINISTRATION, CUTANEOUS; CALCINEURIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MACROLIDES; TACROLIMUS; VITILIGO;

EID: 33644551913     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200607010-00002     Document Type: Review

References (58)

1. Le Poole C, van den Wijngaard RM, Westerhof W, et al. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 1996; 148 (4): 1219-28
2. Tobin DJ, Swanson NN, Pittelkow MR, et al. Melanocytes are not absent in lesional skin of long duration vitiligo. J Pathol 2000; 191 (4): 407-16
3. Jacobson DL, Gange SJ, Rose NR, et al. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997; 84 (3): 223-43
4. Nath SK, Majumder PP, Nordlund JJ. Genetic epidemiology of vitiligo: multilocus recessivity cross-validated. Am J Hum Genet 1994; 55 (5): 981-90
5. Njoo MD, Westerhof W. Vitiligo: pathogenesis and treatment. Am J Clin Dermatol 2001; 2 (3): 167-81
6. van den Wijngaard R, Wankowicz-Kalinska A, Le Poole C, et al. Local immune response in skin of generalized vitiligo patients: destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest 2000; 80 (8): 1299-309
7. van den Wijngaard R, Wankowicz-Kalinska A, Pals S, et al. Autoimmune melanocyte destruction in vitiligo. Lab Invest 2001; 81 (8): 1061-7
8. Montes LF, Abulafia J, Wilborn WH, et al. Value of histopathology in vitiligo. Int J Dermatol 2003; 42 (1): 57-61
9. Lerner AB. Vitiligo. J Invest Dermatol 1959; 32 (2 Pt 2): 285-310
10. Schallreuter KU, Wood JM, Berger J. Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol 1991; 97 (6): 1081-5
11. Schallreuter KU. Effectiveness of pseudocatalase formulations in vitiligo. Clin Exp Dermatol 2003; 28 (5): 562-3
12. Moellmann G, Klein-Angerer S, Scollay DA, et al. Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo. J Invest Dermatol 1982; 79 (5): 321-30
13. Hafez M, Sharaf L, Abd el-Nabi SM. The genetics of vitiligo. Acta Derm Venereol 1983; 63 (3): 249-51
14. Kim SM, Chung HS, Hann SK. The genetics of vitiligo in Korean patients. Int J Dermatol 1998; 37 (12): 908-10
15. Le Poole IC, Das PK, van den Wijngaard RM, et al. Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol 1993; 2 (4): 145-53
16. Tjioe M, Gerritsen MJ, Juhlin L, et al. Treatment of vitiligo vulgaris with narrow band UVB (311 nm) for one year and the effect of addition of folic acid and vitamin B12. Acta Derm Venereol 2002; 82 (5): 369-72
17. Njoo MD, Spuls PI, Bos JD, et al. Nonsurgical repigmentation therapies in vitiligo: meta-analysis of the literature. Arch Dermatol 1998; 134 (12): 1532-40
18. British Photodermatology Group guidelines for PUVA. Br J Dermatol 1994; 130 (2): 246-55
19. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis: photochemotherapy follow-up study. Cancer 1994; 73 (11): 2759-64
20. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44 (5): 755-61
21. Westerhof W, Nieuweboer-Krobotova L. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. Arch Dermatol 1997; 133 (12): 1525-8
22. Tjioe M, Smits T, Van De Kerkhof PCM, et al. The differential effect of broad band versus narrow band UVB with respect to photodamage and cutaneous inflammation. Exp Dermatol 2003; 12 (6): 729-33
23. Njoo MD, Westerhof W, Bos JD, et al. A systematic review of autologous transplantation methods in vitiligo. Arch Dermatol 1998; 134 (12): 1543-9
24. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46 (4): 495-504
25. Mrowietz U, Graeber M, Brautigam M, et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998; 139 (6): 992-6
26. Rappersberger K, Meingassner JG, Fialla R, et al. Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol 1996; 106 (4): 701-10
27. Lener EV, Brieva J, Schachter M, et al. Successful treatment of erosive lichen planus with topical tacrolimus. Arch Dermatol 2001; 137 (4): 419-22
28. Vente C, Reich K, Rupprecht R, et al. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br J Dermatol 1999; 140 (2): 338-42
29. Richter-Hintz D, Schuppe HC, Homey B, et al. Topical tacrolimus (FK 506) is effective in the treatment of pyoderma gangrenosum. J Am Acad Dermatol 2000; 42 (2 Pt 1): 304-5
30. Reich K, Vente C, Neumann C. Topical tacrolimus for pyoderma gangrenosum. Br J Dermatol 1998; 139 (4): 755-7
31. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002; 47 (5): 789-91
32. Reynolds NJ, Al Daraji WI. Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin Exp Dermatol 2002; 27 (7): 555-61
33. Assmann T, Homey B, Ruzicka T. Applications of tacrolimus for the treatment of skin disorders. Immunopharmacology 2000; 47 (2-3): 203-13
34. Bornhovd EC, Schuller E, Bieber T, et al. Immunosuppressive macrolides and their use in dermatology [in German]. Hautarzt 2000; 51 (9): 646-54
35. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002; 46 (2): 228-41
36. Castanet J, Ortonne JP. Pathophysiology of vitiligo. Clin Dermatol 1997; 15 (6): 845-51
37. Ogg GS, Rod Dunbar P, Romero P, et al. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998; 188 (6): 1203-8
38. Yeo UC, Yang YS, Park KB, et al. Serum concentration of the soluble interleukin-2 receptor in vitiligo patients. J Dermatol Sci 1999; 19 (3): 182-8
39. Caixia T, Hongwen F, Xiran L. Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo. J Dermatol Sci 1999; 21 (1): 59-62
40. Grimes PE, Morris R, Avaniss-Aghajani E, et al. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004; 51 (1): 52-61
41. Lepe V, Moncada B, Castanedo-Cazares JP, et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139 (5): 581-5
42. Tanghetti EA. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series. Cutis 2003; 71 (2): 158-62
43. Travis LB, Weinberg JM, Silverberg NB. Successful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol 2003; 139 (5): 571-4
44. Castanedo-Cazares JP, Lepe V, Moncada B. Repigmentation of chronic vitiligo lesions by following tacrolimus plus ultraviolet-B-narrow-band. Photodermatol Photoimmunol Photomed 2003; 19 (1): 35-6
45. Smith DA, Tofte SJ, Hanifin JM. Repigmentation of vitiligo with topical tacrolimus. Dermatology 2002; 205 (3): 301-3
46. Mayoral FA, Gonzalez C, Shah NS, et al. Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology 2003; 207 (3): 322-3
47. Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998; 111 (3): 396-8
48. Bos JD. Topical tacrolimus and pimecrolimus are not associated with skin atrophy [letter]. Br J Dermatol 2002; 146 (2): 342
49. Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001; 144 (3): 507-13
50. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998; 102 (4 Pt 1): 637-44
51. Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001; 44 (1 Suppl.): S28-38
52. Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000; 136 (8): 999-1006
53. Kawalek AZ, Spencer JM, Phelps RG. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg 2004; 30 (2 Pt 1): 130-5
54. Passeron T, Ostovari N, Zakaria W, et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004; 140 (9): 1065-9
55. Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000; 9 (3): 165-9
56. Wester RC, Maibach HI. In vivo percutaneous absorption. In: Marzulli FN, Maibach HI, editors. Dermatoxicology. 2nd ed. Washington, DC: Hemisphere Publishing Corporation, 1983: 131-46
57. Gutzmer R, Volker B, Kapp A, et al. Successful topical treatment of cutaneous sarcoidosis with tacrolimus [in German]. Hautarzt 2003; 54 (12): 1193-7
58. Katoh N, Mihara H, Yasuno H. Cutaneous sarcoidosis successfully treated with topical tacrolimus. Br J Dermatol 2002; 147 (1): 154-6